Baxter International Inc  

(Public, NYSE:BAX)   Watch this stock  
Find more results for BAX
-0.16 (-0.42%)
Nov 25 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 37.72 - 38.08
52 week 32.18 - 43.44
Open 38.08
Vol / Avg. 2.68M/5.07M
Mkt cap 20.81B
P/E 28.25
Div/yield 0.12/1.21
EPS 1.34
Shares 547.02M
Beta 0.68
Inst. own 86%
Jan 27, 2016
Q4 2015 Baxter International Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Nov 17, 2015
Baxter International Inc at Stifel Healthcare Conference - Webcast
Nov 11, 2015
Baxter International Inc at Credit Suisse Healthcare Conference - Webcast
Oct 27, 2015
Q3 2015 Baxter International Inc Earnings Release
Oct 27, 2015
Q3 2015 Baxter International Inc Earnings Call - Webcast
Sep 17, 2015
Baxter International Inc at Morgan Stanley Healthcare Conference
Sep 9, 2015
Baxter International Inc. at Goldman Sachs European Medtech & Healthcare Services Conference
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 0.08% 11.67%
Operating margin -1.53% 15.82%
EBITD margin - 25.92%
Return on average assets 0.03% 7.61%
Return on average equity 0.10% 23.47%
Employees 66,000 -
CDP Score - 78 C


One Baxter Pkwy, Df2-1W
DEERFIELD, IL 60015-4625
United States - Map
+1-847-9482000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia


Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment, which include three commercial franchises: Hemophilia, BioTherapeutics and BioSurgery, and Medical Products segment, which include four commercial franchises: Fluid Systems, Renal, Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions, and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps and inhalation anesthetics. Its products are used in hospitals, kidney dialysis centers and nursing homes, among others.

Officers and directors

Robert L. Parkinson Jr. Chairman Emeritus
Age: 64
Bio & Compensation  - Reuters
Robert J. Hombach CPA Chief Financial Officer, Corporate Vice President
Age: 49
Bio & Compensation  - Reuters
David P. Scharf Corporate Vice President, General Counsel
Age: 47
Bio & Compensation  - Reuters
Jeanne K. Mason Ph.D. Corporate Vice President - Human Resources
Age: 59
Bio & Compensation  - Reuters
Ludwig N. Hantson Ph.D. Corporate Vice President, President - BioScience
Age: 52
Bio & Compensation  - Reuters
Peter S. Hellman Lead Independent Director
Age: 65
Bio & Compensation  - Reuters
Michael F. Mahoney Director
Age: 50
Bio & Compensation  - Reuters
Thomas F. Chen Independent Director
Age: 65
Bio & Compensation  - Reuters
Uma Chowdhry Ph.D. Independent Director
Age: 67
Bio & Compensation  - Reuters
Blake E. Devitt Independent Director
Age: 68
Bio & Compensation  - Reuters